摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-溴-6-异丙氧基吡啶 | 463336-87-0

中文名称
2-溴-6-异丙氧基吡啶
中文别名
2-溴-6-(1-甲基乙氧基)-吡啶
英文名称
2-bromo-6-isopropoxypyridine
英文别名
2-bromo-6-propan-2-yloxypyridine
2-溴-6-异丙氧基吡啶化学式
CAS
463336-87-0
化学式
C8H10BrNO
mdl
——
分子量
216.077
InChiKey
RBQOILDHZGNUQT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    235.8±20.0 °C(Predicted)
  • 密度:
    1.383±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3
  • 重原子数:
    11
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.38
  • 拓扑面积:
    22.1
  • 氢给体数:
    0
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2933399090
  • 储存条件:
    室温、密封保存,并保持干燥。

SDS

SDS:8acfd74f9e63add9a311d1c6acad1fe6
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 2-Bromo-6-isopropoxypyridine
Synonyms: 6-Bromo-2-isopropoxypyridine

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 2-Bromo-6-isopropoxypyridine
CAS number: 463336-87-0

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H10BrNO
Molecular weight: 216.1

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] AZOLE COMPOUNDS AS PIM INHIBITORS<br/>[FR] COMPOSÉS D'AZOLE UTILISÉS EN TANT QU'INHIBITEURS DES PIM
    申请人:AMGEN INC
    公开号:WO2012129338A1
    公开(公告)日:2012-09-27
    The invention relates to bicyclic compounds of formulas I and Ia, and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of Pim-1 and/or Pim-2, and/or Pim-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of Pim kinase related conditions and diseases, preferably cancer.
    该发明涉及公式I和Ia的双环化合物及其盐。在某些实施例中,该发明涉及Pim-1和/或Pim-2和/或Pim-3蛋白激酶活性或酶功能的抑制剂或调节剂。在更进一步的实施例中,该发明涉及包含本文所披露的化合物的药物组合物,以及它们在预防和治疗Pim激酶相关疾病和病症,尤其是癌症中的用途。
  • [EN] 2,3-DISUBSTITUTED 1 -ACYL-4-AMINO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS<br/>[FR] DÉRIVÉS 2,3-DISUBSTITUÉS DE 1-ACYL-4-AMINO-1,2,3,4-TÉTRAHYDROQUINOLÉINE ET LEUR UTILISATION COMME INHIBITEURS DE BROMODOMAINES
    申请人:GLAXOSMITHKLINE IP NO 2 LTD
    公开号:WO2014140076A1
    公开(公告)日:2014-09-18
    The present invention relates to novel compounds of formula (I), wherein R1 is C1-4alkyl; R2 is C1-4alkyl, C3-7cycloalkyl, -CH2CF3, -CH2OCH3 or heterocyclyl; R3 is C1-4alkyl, -CH2F, -CH2OH or -CH2O(O)CH3; R4 when present is as defined in claim 1; R5 when present is H, halo, hydroxy or C1-6alkoxy; A is -NH-, -O-, -S-, -SO-, -SO2-, -N(C1-4alkyl)- or -NC(O)(CH3)-; V is phenyl, heteroaromatic or pyridone any of which may be optionally substituted by 1, 2 or 3 substituents; W is CH or N; X is C or N; Y is C or N; and Z is CH or N; subject to the proviso that no more than 2 of W, X, Y and Z are N, pharmaceutical compositions containing such compounds and to their use as bromodomain inhibitors.
    本发明涉及式(I)的新化合物,其中R1为C1-4烷基;R2为C1-4烷基、C3-7环烷基、-CH2CF3、-CH2OCH3或杂环烷基;R3为C1-4烷基、-CH2F、-CH2OH或-CH2O(O)CH3;R4存在时如权利要求1所定义;R5存在时为H、卤素、羟基或C1-6烷氧基;A为-NH-、-O-、-S-、-SO-、-SO2-、-N(C1-4烷基)-或-NC(O)(CH3)-;V为苯基、杂芳基或吡啶酮,其中任何一个可以选择性地被1、2或3个取代基取代;W为CH或N;X为C或N;Y为C或N;Z为CH或N;但W、X、Y和Z中不超过2个为N,含有这种化合物的药物组合物以及它们作为溴结构域抑制剂的用途。
  • HETEROCYCLIC COMPOUND
    申请人:TAKEDA PHARMACEUTICAL COMPANY LIMITED
    公开号:US20160159773A1
    公开(公告)日:2016-06-09
    The present invention provides an agent for the prophylaxis or treatment of autoimmune diseases (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus etc.) and the like, which has a superior Tyk2 inhibitory action. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.
    本发明提供了一种用于预防或治疗自身免疫性疾病(例如牛皮癣、类风湿关节炎、炎症性肠病、干燥综合征、贝赫切特病、多发性硬化症、系统性红斑狼疮等)等的药剂,其具有优越的Tyk2抑制作用。 本发明涉及一种由下式表示的化合物 其中每个符号如规范中定义的,或其盐。
  • TGF BETA R ANTAGONISTS
    申请人:Bristol-Myers Squibb Company
    公开号:US20160176871A1
    公开(公告)日:2016-06-23
    The invention relates generally to compounds that modulate the activity of TGFβR-1 and TGFβR-2, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.
    这项发明通常涉及调节TGFβR-1和TGFβR-2活性的化合物,包含这些化合物的药物组合物以及利用该发明的化合物治疗增殖性疾病和失调凋亡疾病(如癌症)的方法。
  • [EN] BIARYL DERIVATIVES AS GPR120 AGONISTS<br/>[FR] DÉRIVÉS DE BIARYLE EN TANT QU'AGONISTES DE GPR120
    申请人:LG LIFE SCIENCES LTD
    公开号:WO2014209034A1
    公开(公告)日:2014-12-31
    The present invention relates to biaryl derivatives of Formula 1, a method for preparing the same, a pharmaceutical composition comprising the same and use thereof. The biaryl derivatives of Formula 1 according to the present invention promote GLP-1 formation in the gastrointestinal tract and improve insulin resistance in the liver or in muscle due to anti-inflammatory action in macrophages, lipocytes, etc., and can accordingly be effectively used for preventing or treating diabetes, complications of diabetes, obesity, non-alcoholic fatty liver, steatohepatitis, osteoporosis or inflammation.
    本发明涉及公式1的联苯衍生物,一种制备该联苯衍生物的方法,包含该联苯衍生物的药物组合物以及其用途。根据本发明的公式1的联苯衍生物促进胃肠道中GLP-1的形成,并由于巨噬细胞、脂肪细胞等中的抗炎作用改善肝脏或肌肉中的胰岛素抵抗,因此可有效用于预防或治疗糖尿病、糖尿病并发症、肥胖、非酒精性脂肪肝、脂肪性肝炎、骨质疏松症或炎症。
查看更多